Glutamatergic hypothesis in schizophrenia: Clinical studies with ketamine contribution;Hypothèse glutamatergique de la schizophrénie: Apports des recherches cliniques sur la kétamine

Encephale

Volumn 27, Issue 1, 2001, Pages 53-59

  Mechri, A ^a,b   Saoud, M ^a,c   Khiari, G ^a   D'Amato, T ^a,b,c   Dalery, J ^a   Gaha, L ^b  

^a Service de Psychiatrie   (Tunisia)

^b CENTRE HOSPITALIER LE VINATIER   (France)

^c INSERM   (France)

Author keywords

Glutamate; Ketamine; N methyl D aspartate receptor; Psychosis; Schizophrenia

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; HUMAN; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; SCHIZOPHRENIA;

BRAIN; GLUTAMINE; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 1142302573     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Corticolimbic dopamine neurotransmission is temporally disociated from the cognitive and locomotor effects of phencyclidine
2. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
3. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine
4. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
5. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
6. The schizophrenia ketamine challenge study debate
7. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia
8. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
9. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: Support for NMDA response involvement in responses to subanesthetic dose of ketamine
10. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia
11. Recent advances in the phencyclidine model of schizophrenia
12. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
13. Hypothèse glutamatergique de la schizophrénie: Des psychoses induites par la phencyclidine au déséquilibre corticosous-cortical
14. Acide aminés excitateurs, une nouvelle classe de neurotransmetteurs
15. Subanesthesic effects of the noncompetitive NMDA antagonist, ketamine in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses
16. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
17. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
18. Effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions
19. Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients
20. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
21. Subanesthesic doses of ketamine stimulate psychosis in schizophrenia
22. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
23. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
24. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine
25. The apolipoprotein E 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia
26. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
27. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice
28. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
29. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment of psychosis
30. The effects of a subanesthesic dose of ketamine on selective attention
31. Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?
32. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats
33. Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions
34. Glutamatergic aspects of schizophrenia
35. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
36. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy
37. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission topography (PET) and [18F] fluorodeoxyglucose (FDG)
38. Effects of (S)-ketamine on striatal dopamine: A [11C] raclopride PET study of a model psychosis in humans
39. Ketamine: Its pharmacology and therapeutic uses